Literature DB >> 27964820

T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints.

Reza Mirzaei1, Susobhan Sarkar1, V Wee Yong2.   

Abstract

Glioblastoma is an aggressive and incurable primary brain tumor. While the blockade of immune checkpoints leads to reversal of T cell exhaustion in many cancers, the efficacy of this therapy in glioblastoma requires further consideration of the brain microenvironment beyond T cell activity. Neural cells are crucially dependent on glucose for survival, and tumor cells rabidly consume glucose; the glucose-deprived microenvironment further elevates immune checkpoint molecules to benefit tumor growth and exacerbate T cell exhaustion. We review here how immune checkpoints drive exhaustion in T cells while favoring tumor metabolism, and discuss how glucose competition in the unique CNS milieu is an important consideration to improve the outcomes of immune checkpoint blockade in glioblastoma.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27964820     DOI: 10.1016/j.it.2016.11.005

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  45 in total

1.  Blockade of CD73 delays glioblastoma growth by modulating the immune environment.

Authors:  J H Azambuja; R S Schuh; L R Michels; I C Iser; L R Beckenkamp; G G Roliano; G S Lenz; J N Scholl; J Sévigny; M R Wink; M A Stefani; A M O Battastini; F Figueiró; H F Teixeira; E Braganhol
Journal:  Cancer Immunol Immunother       Date:  2020-04-29       Impact factor: 6.968

2.  Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma.

Authors:  Abhishek D Garg; Lien Vandenberk; Matthias Van Woensel; Jochen Belmans; Marco Schaaf; Louis Boon; Steven De Vleeschouwer; Patrizia Agostinis
Journal:  Oncoimmunology       Date:  2017-03-03       Impact factor: 8.110

3.  In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment.

Authors:  Guranda Chitadze; Charlotte Flüh; Elgar Susanne Quabius; Sandra Freitag-Wolf; Christian Peters; Marcus Lettau; Jaydeep Bhat; Daniela Wesch; Hans-Heinrich Oberg; Stefanie Luecke; Ottmar Janssen; Michael Synowitz; Janka Held-Feindt; Dieter Kabelitz
Journal:  Oncoimmunology       Date:  2017-08-08       Impact factor: 8.110

4.  GCN2 is essential for CD8+ T cell survival and function in murine models of malignant glioma.

Authors:  Aida Rashidi; Jason Miska; Catalina Lee-Chang; Deepak Kanojia; Wojciech K Panek; Aurora Lopez-Rosas; Peng Zhang; Yu Han; Ting Xiao; Katarzyna C Pituch; Julius W Kim; Mahsa Talebian; Jawad Fares; Maciej S Lesniak
Journal:  Cancer Immunol Immunother       Date:  2019-12-16       Impact factor: 6.968

Review 5.  CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.

Authors:  Stephen J Bagley; Arati S Desai; Gerald P Linette; Carl H June; Donald M O'Rourke
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

Review 6.  Current state and future prospects of immunotherapy for glioma.

Authors:  Neha Kamran; Mahmoud S Alghamri; Felipe J Nunez; Diana Shah; Antonela S Asad; Marianela Candolfi; David Altshuler; Pedro R Lowenstein; Maria G Castro
Journal:  Immunotherapy       Date:  2018-02-01       Impact factor: 4.196

7.  T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.

Authors:  Karolina Woroniecka; Pakawat Chongsathidkiet; Kristen Rhodin; Hanna Kemeny; Cosette Dechant; S Harrison Farber; Aladine A Elsamadicy; Xiuyu Cui; Shohei Koyama; Christina Jackson; Landon J Hansen; Tanner M Johanns; Luis Sanchez-Perez; Vidyalakshmi Chandramohan; Yen-Rei Andrea Yu; Darell D Bigner; Amber Giles; Patrick Healy; Glenn Dranoff; Kent J Weinhold; Gavin P Dunn; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2018-02-07       Impact factor: 12.531

8.  Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy.

Authors:  Carmela Passaro; Quazim Alayo; Isabella De Laura; John McNulty; Korneel Grauwet; Hirotaka Ito; Vivek Bhaskaran; Marco Mineo; Sean E Lawler; Khalid Shah; Maria C Speranza; William Goins; Eric McLaughlin; Soledad Fernandez; David A Reardon; Gordon J Freeman; E Antonio Chiocca; Hiroshi Nakashima
Journal:  Clin Cancer Res       Date:  2018-10-02       Impact factor: 12.531

9.  Radiomic profiles in diffuse glioma reveal distinct subtypes with prognostic value.

Authors:  Peng Lin; Yu-Ting Peng; Rui-Zhi Gao; Yan Wei; Xiao-Jiao Li; Su-Ning Huang; Ye-Ying Fang; Zhu-Xin Wei; Zhi-Guang Huang; Hong Yang; Gang Chen
Journal:  J Cancer Res Clin Oncol       Date:  2020-02-17       Impact factor: 4.553

10.  RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma.

Authors:  Stephen J Bagley; Wei-Ting Hwang; Steven Brem; Gerald P Linette; Donald M O'Rourke; Arati S Desai
Journal:  J Neurooncol       Date:  2018-10-23       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.